[1] Maeda H,Wu J,Sawa T,et al.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review[J]. J Control Release, 2000,65(1-2): 271.
[2] Yang T, Choi MK,Cui FD,et al.Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome[J]. J Control Release, 2007,120(3): 169.
[3] Wang Y, Drummond DC,SHao Y,et al.Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines[J]. Int J Pharm, 2007. 337(1-2): 63.
[4] Dagar S, Drummond DC,Noble CO,et al.VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies[J]. J Control Release, 2003,91(1-2): 123.
[5] Allen T M. and P.R. Cullis, Drug delivery systems: entering the mainstream. Science, 2004,303(5665): 1818.
[6] Hobbs, S.K, et al.Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment[J]. Proc Natl Acad Sci U S A, 1998,95(8): 4607.
[7] Heldin, C.H, et al.High interstitial fluid pressure-an obstacle in cancer therapy[J]. Nat Rev Cancer, 2004,4(10): 806.
[8] Gabizon, A, et al.In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice[J]. Clin Cancer Res, 2003,9(17): 6551.
[9] Gryparis, E.C, et al.Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells[J]. Eur J Pharm Biopharm, 2007. 67(1): 1.
[10] Gabizon, A.A, H. Shmeeda, and S. Zalipsky, Pros and cons of the liposome platform in cancer drug targeting[J]. J Liposome Res, 2006,16(3): 175.
[11] Gerweck, L.E. and K. Seetharaman, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res, 1996,56(6): 1194.
[12] Egeblad, M. and Z. Werb, New functions for the matrix metalloproteinases in cancer progression[J]. Nat Rev Cancer, 2002,2(3): 161.
[13] van Sluis, R, et al.In vivo imaging of extracellular pH using 1H MRSI. Magn Reson Med, 1999,41(4): 743.
[14] Stubbs, M, et al.Causes and consequences of tumour acidity and implications for treatment[J]. Mol Med Today, 2000,6(1):15.
[15] Yamagata, M, et al.The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase[J]. Br J Cancer, 1998,77(11): 1726.
[16] Mohajer, G., E.S. Lee, and Y.H. Bae, Enhanced intercellular retention activity of novel pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells[J]. Pharm Res, 2007,24(9): 1618.
[17] Ko, J., et al.Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy[J]. J Control Release, 2007,123(2): 109.
[18] Lee, E.S, et al.Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)[J]. J Control Release, 2007. 123(1): 19.
[19] Lee, E.S, et al.Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance[J]. J Control Release, 2008,129(3): 228.
[20] Sawant, R.M,et al."SMART"drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers[J]. Bioconjug Chem, 2006,17(4): 943.
[21] Sethuraman, V.A. and Y.H. Bae, TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors[J]. J Control Release, 2007,118(2): 216.
[22] Kessenbrock, K, V. Plaks, and Z. Werb, Matrix metalloproteinases: regulators of the tumor microenvironment[J]. Cell, 2010,141(1): 52.
[23] Chau, Y., F.E. Tan, and R. Langer. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX[J]. Bioconjug Chem, 2004,15(4): 931.
[24] Chau, Y, et al.Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models[J]. Int J Cancer, 2006,118(6): 1519.
[25] Hatakeyama, H, et al.Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipi[J]d. Gene Ther, 2007,14(1): 68.
[26] Mok, H, et al.PEGylated and MMP-2 specifically dePEGylated quantum dots: comparative evaluation of cellular uptake[J]. Langmuir, 2009,25(3): 1645.